Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

COMPLETED Phase 2

A Second Trial of the Abbreviated Protocol Two-Stage Exchange

NCT05607030 · View on ClinicalTrials.gov ↗

Study Summary

Apex-2 is a multi-site, parallel group, randomized trial. Patients will be randomly assigned in a 1:1 ratio to the Experimental Arm or the Control Arm. The objective of the study is to evaluate safety and determine efficacy of the VT-X7 system. Efficacy is evaluated as superiority of the Experimental Arm in a composite endpoint of Overall Success at 180 days, consisting of a revision prosthesis implanted at Stage 2, absence of periprosthetic joint infection (PJI), absence of continued antibiotic therapy for treatment or prophylaxis of PJI, absence of revision surgery and absence of mortality. Secondary objectives are to evaluate overall success at 365 days, overall safety of the VT-X7 procedure, quality of life (QoL), and patient survival. The exploratory objective is to compare Experimental and Control Arms in exploratory endpoints. Follow-up: Patients will be evaluated at 90-, 180-, and 365-day follow-up visits.

Conditions Studied

Interventions

  • COMBINATION_PRODUCT VT-X7 Treatment System
  • PROCEDURE Two-stage exchange arthroplasty
  • DRUG SOC Antibiotics
  • DRUG Experimental Antibiotics

Study Locations (19)

Ohio

  • University of Cincinnati — Cincinnati
  • Bethesda North Hospital - TriHealth Hatton Research — Cincinnati
  • Cleveland Clinic — Cleveland
  • The Ohio State University Medical Center — Columbus

Florida

  • Kennedy White Orthopaedic Center — Sarasota
  • Cleveland Clinic Florida — Weston

Pennsylvania

  • Rothman Orthopaedic Institute — Philadelphia
  • University of Pittsburgh Medical Center — Pittsburgh

Arizona

  • Banner - University Medical Center Phoenix — Phoenix

California

  • Harbor UCLA Medical Center — Los Angeles

Michigan

  • Covenant Medical Center — Saginaw

Minnesota

  • Mayo Clinic — Rochester

Missouri

  • University of Missouri — Columbia

Trial Details

FieldValue
Enrollment Target 76 participants
Start Date 2023-01-23
Est. Completion 2024-10-30
Phase Phase 2

Sponsor

Osteal Therapeutics

2 total trials

Interested in This Trial?

Always speak with your doctor before enrolling in a clinical trial.

Full Details on ClinicalTrials.gov ↗

What the Registry Record Tells You About NCT05607030

The ClinicalTrials.gov registry entry for NCT05607030 describes a study currently listed as completed. It is categorized as Phase 2, which is the standard way researchers label where a study sits along the investigational pathway from early safety work through later efficacy and post-marketing evaluation. The registered enrollment target is 76 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Osteal Therapeutics, which has 2 total studies on file at ClinicalTrials.gov, and sponsors are the parties responsible for study design, oversight, and regulatory filings.

The record links to 1 condition, with Prosthetic-joint Infection appearing as the primary indexed condition, and to 4 interventions — of which VT-X7 Treatment System is the first listed. Interventions can include drugs, devices, procedures, behavioral programs, or observational arms, and each is tracked as a separate registry field so that downstream queries can filter accurately. When a trial lists multiple interventions, it usually reflects a multi-arm design or a comparison protocol rather than a single treatment being tested in isolation. The brief summary published in the registry is the clearest source of protocol intent and should be read before drawing conclusions from any sidebar tags.

Geographic footprint matters for practical reasons: NCT05607030 reports 19 study locations spanning 14 distinct geographic areas — top geographies include Ohio, Florida, Pennsylvania. A larger site network tends to correlate with broader recruitment capacity, but it does not imply anything about study quality, and site-level enrollment status can diverge from the overall registry status shown above. Every data point on this page comes from the public ClinicalTrials.gov dataset and is reproduced here for reference only; it is not a medical recommendation, an endorsement of the sponsor, or an invitation to enroll. Verify current status, eligibility criteria, and contact details directly at ClinicalTrials.gov, and discuss any participation decision with your own healthcare provider.

Frequently Asked Questions

What is clinical trial NCT05607030 about?

NCT05607030 is a clinical study titled "A Second Trial of the Abbreviated Protocol Two-Stage Exchange". Apex-2 is a multi-site, parallel group, randomized trial. Patients will be randomly assigned in a 1:1 ratio to the Experimental Arm or the Control Arm. The objective of the study is to evaluate safety and determine efficacy of the VT-X7 system. Efficacy is evaluated as superiority of the Experiment...

What is the current status of trial NCT05607030?

This trial is currently completed. It is a Phase 2 study. The enrollment target is 76 participants. The study started on 2023-01-23. Estimated completion is 2024-10-30.

What conditions does trial NCT05607030 study?

This clinical trial studies the following conditions: Prosthetic-joint Infection. These conditions were identified from the trial registry and reflect the primary focus areas of the research.

What interventions are being tested in trial NCT05607030?

The interventions under investigation include: VT-X7 Treatment System (COMBINATION_PRODUCT), Two-stage exchange arthroplasty (PROCEDURE), SOC Antibiotics (DRUG), Experimental Antibiotics (DRUG). Each intervention is being evaluated for safety and efficacy as part of this clinical study.

Who is sponsoring clinical trial NCT05607030?

This trial is sponsored by Osteal Therapeutics, which has 2 total clinical trials registered on ClinicalTrials.gov. The sponsor is responsible for the study's design, funding, and regulatory compliance.

Where is trial NCT05607030 being conducted?

This trial has 19 study locations across Arizona, California, Florida, Michigan, Minnesota. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.

Related

Data sourced from official U.S. government datasets. See our methodology for details. Retrieved and formatted by PlainTrial Editorial